Verification of risk scores to predict intravenous immunoglobulin resistance in incomplete XXXX .

@entity1 @entity573 @entity617
BACKGROUND: A recent study indicated the efficacy of the addition of @entity617 to intravenous immunoglobulin (IVIG) as initial treatment in @entity1 with higher risk of IVIG resistance. Several different risk scores for predicting IVIG resistance have been proposed mainly based on typical @entity573 ( @entity573 ) @entity1 . We investigated the utility of the risk scores to predict IVIG resistance with incomplete @entity573 . METHODS: Clinical records of incomplete @entity573 @entity1 who received a single dose of IVIG between 2005 and 2012 at our institute were retrospectively reviewed. @entity1 were classified into an IVIG-responsive group and an IVIG-resistant group. The Kobayashi, Egami, and Sano risk scores were calculated for each @entity1 and the proportion of high-risk @entity1 was compared between the two groups for each risk score. RESULTS: For 51 incomplete @entity573 @entity1 , Kobayashi (66.7% versus 47.6%, P   =   0.253), Egami (55.6% versus 38.1%, P   =   0.274), and Sano (57.1% versus 10.8%, P   =   0.068) risk scores identified a higher proportion of high-risk @entity1 in the IVIG-resistant group compared to the IVIG-responsive group, but significant difference was not observed. The Sano risk score showed the highest odds ratio (6.19, 95% confidence interval 1.00-38.26). CONCLUSIONS: The proportion of @entity1 identified as being at high-risk for IVIG resistance using the Kobayashi, Egami, and Sano risk scores, respectively, were not significantly different between the IVIG-responsive group and the IVIG-resistant group with incomplete @entity573 . Among the three risk scores, the Sano risk score has the best ability to predict IVIG resistance with incomplete @entity573 . This article is protected by copyright. All rights reserved.
